Can Viibryd (vilazodone) be taken during pregnancy?

Viibryd (Vilazodone) Use During Pregnancy

Viibryd can be taken during pregnancy only after careful risk-benefit discussion with your healthcare provider, as it may increase the risk of neonatal complications when taken late in pregnancy, though the decision to continue should prioritize maternal mental health and functioning. 1

FDA Labeling Guidance

The FDA medication guide for Viibryd explicitly states that taking the medication late in pregnancy may lead to increased risk of certain problems in the newborn, and advises pregnant women to discuss the risks with their healthcare provider. 1 Specifically, the FDA warns that use late in pregnancy may lead to:

• Neonatal complications requiring prolonged hospitalization 1
• Respiratory support needs 1
• Tube feeding requirements 1
• Persistent pulmonary hypertension of the newborn (PPHN) 1

Risk-Benefit Framework

The decision to use Viibryd during pregnancy should not result in automatic discontinuation if the medication is required for daily functioning of the pregnant person. 2 This aligns with general principles for antidepressant management during pregnancy, where the consensus is that documented risks are very low and treatment should not be stopped if required for maternal functioning. 2

Key Considerations:

• Untreated depression poses significant risks to both mother and fetus, and these risks must be weighed against medication risks 2
• The FDA requires healthcare providers to inform pregnant patients about the National Pregnancy Registry for Antidepressants (1-844-405-6185) to collect safety data 1
• Patients should notify their healthcare provider immediately if they become pregnant while taking Viibryd 1

Emerging Preclinical Safety Concerns

Recent animal studies raise significant concerns about vilazodone's safety profile during pregnancy, though human data remain limited. A 2024 preclinical study demonstrated that prenatal vilazodone exposure at therapeutic-equivalent doses caused:

• Maternal toxicity with reduced food intake and weight gain 3
• Embryo-fetal toxicity including smaller litter sizes and decreased fetal/placental weights 3
• Developmental neurotoxicity with decreased fetal brain size and weight 3
• Disruption of BDNF/Bax-Bcl2/5-HT signaling pathways critical for brain development 3
• Long-lasting neurobehavioral impairments in offspring, including increased depressive and anxiety-like behaviors 4

These findings represent the first documentation of adverse effects of vilazodone on fetal brain development, though extrapolation from animal studies to humans requires caution. 3

Clinical Decision Algorithm

If currently taking Viibryd and planning pregnancy:

• Attempt gradual discontinuation before conception if it will not severely impact daily functioning 2
• If discontinuation is not feasible, continue at the lowest effective dose or consider intermittent use 2

If already pregnant while taking Viibryd:

• Do not abruptly discontinue, as this can cause serious withdrawal effects 1
• Engage in detailed risk-benefit discussion with your provider 2
• Consider whether intermittent use (as-needed basis) could maximize functioning while reducing fetal exposure 2
• Monitor pregnancy carefully, including fetal growth and maternal blood pressure 2

Alternative considerations:

• Switching to antidepressants with more established pregnancy safety data may be considered, though vilazodone's reproductive safety profile remains inadequately characterized 5
• The lack of comprehensive human data on vilazodone's reproductive safety is a significant knowledge gap 5

Important Caveats

• Limited human data: Questions remain regarding vilazodone's reproductive safety profile, with insufficient evidence-based information for most drugs used during pregnancy 5, 6
• Timing matters: The greatest concern appears to be use late in pregnancy due to neonatal adaptation issues 1
• No drug is risk-free: Great caution should be taken when prescribing any medication in pregnancy, as no drug is entirely without side effects 7
• Individual variation: The magnitude of risk may vary based on dose, timing of exposure, and individual patient factors 3